Kurin Commends the CDC for Their Recent Publication on Blood Culture Contamination

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, commends the Centers for Disease Control and Prevention (CDC) for their just-released publication on blood culture contamination. The paper stresses the importance of reducing these preventable contaminations and highlights how devices, like Kurin, have been shown to be effective in this regard. The CDC specifically states: “There are devices that are commercially available that have shown promise in further reducing blood culture contamination rates. These devices initially divert a small amount of potentially contaminated blood and then collect blood for the blood culture.”

“We are pleased to see the CDC use their resources to address this serious clinical challenge” said Bob Rogers, CEO of Kurin, Inc. “The CDC cited the small amount of blood these devices use to prevent the initial blood from entering the blood culture bottle and thus reduce contaminations. The CDC also shared that the average contamination costs approximately $4500, showing there is a financial impact as well as negative health consequences from these contaminations. Kurin is the market leader because of its simplicity and the small amount of blood used, and we look forward to working in concert with the CDC on this important issue.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

The new document can be found at: https://www.cdc.gov/antibiotic-use/core-elements/pdfs/fs-bloodculture-508.pdf

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.